KCPG
ARIA

Kavar Capital Partners Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Kavar Capital Partners Group’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,500
Closed -$12K – 521
2014
Q1 		$12K Hold
1,500
– – 0.01% 306
2013
Q4 		$10K Buy
+1,500
New +$8.1K 0.01% 300

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kavar Capital Partners Group's ARIA Position: Q2 2014 in Review

Kavar Capital Partners Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2014, closing a stake of 1,500 shares — an estimated $12K sold.

Kavar Capital Partners Group first reported a position in ARIA in Q4 2013 and held it in 2 quarters. The position peaked at $12K in Q1 2014. 169 funds tracked by Wall St. Rank hold ARIA as of Q2 2014.

  • Kavar Capital Partners Group reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Kavar Capital Partners Group sold 1,500 Ariad Pharmaceuticals Inc shares in Q2 2014, an estimated $12K.
  • Kavar Capital Partners Group first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 2 quarters.
  • Kavar Capital Partners Group's Ariad Pharmaceuticals Inc position peaked at $12K in Q1 2014.
  • 169 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2014.

Based on Kavar Capital Partners Group's 13F filing for Q2 2014, filed 25 Jan 2019.